Patrick SoonShiong - NantHealth Insider

NH -- USA Stock  

USD 3.18  0.11  3.58%

  Founder
Dr. Patrick SoonShiong, M.D. is Chairman of the Board, Chief Executive Officer, Founder of the Company. In 2011, he founded NantWorks, an ecosystem of companies to create a transformative global health information and next generation pharmaceutical development network for the secure sharing of genetic and medical information, where he currently serves as Chief Executive Officer and Chairman of the board of directors. NantWorks is an affiliate and significant stockholder of NantHealth and Dr. Patrick SoonShiong indirectly controls all of the equity interests of NantWorks. Dr. Patrick SoonShiong, a physician, surgeon and scientist, has pioneered novel therapies for both diabetes and cancer, published over 100 scientific papers, and has over 95 issued patents on groundbreaking advancements spanning myriad fields. Dr. Patrick SoonShiong performed the worlds first encapsulated human islet transplant, the first engineered islet cell transplant and the first pig to man islet cell transplant in diabetic patients. He invented and developed Abraxane, the nations first FDAapproved protein nanoparticle albuminbound delivery technology for the treatment of cancer. The Friends of the National Library of Medicine has honored him with their Distinguished Medical Science Award. Dr. Patrick SoonShiong holds a degree in medicine from the University of the Witwatersrand and a M.Sc. in science from the University of British Columbia. Dr. Patrick SoonShiong is a board certified surgeon and a fellow of the American College of Surgeons and of the Royal College of Physicians and Surgeons of Canada.
Age: 63  Founder Since 2016  Ph.D    
310-883-1300  http://nanthealth.com
SoonShiong serves as Chairman of the Chan SoonShiong Family Foundation and Chairman and CEO of the Chan SoonShiong Institute of Molecular Medicine, a nonprofit medical research organization. He currently cochairs the CEO Council for Health and Innovation at the Bipartisan Policy Center and is a member of the Global Advisory Board of Bank of America.

Patrick SoonShiong Latest Insider Activity

Management Efficiency

The company has Return on Asset (ROA) of (7.45) % which means that for every 100 dollars spent on asset it generated loss of $7.45. This is way below average. Likewise, it shows return on total equity (ROE) of (46.34) % which implies that it produced no returns to current stockholders.
The company reports 196.65 M of total liabilities with total debt to equity ratio (D/E) of 114.9 which implies that the company may not be able to produce enough cash to satisfy its debt commitments. NantHealth has Current Ratio of 1.86 which is generally considered normal.

Similar Executives

Found 1 records

FOUNDER Since

Seth BlackleyEvolent Health
2018

Entity Summary

NantHealth, Inc., together with its subsidiaries, operates as an evidence-based personalized healthcare company in the United States and internationally. The company was founded in 2010 and is headquartered in Culver City, California. NantHealth operates under Health Information Services classification in USA and traded on BATS Exchange. It employs 494 people.NantHealth (NH) is traded on BATS Exchange in USA. It is located in CALIFORNIA U.S.A and employs 494 people. NantHealth is listed under Business Services category by Fama And French industry classification.

NantHealth Leadership Team

Michael Blaszyk, Independent Director
Kirk Calhoun, Independent Director
Mark Burnett, Independent Director
Patrick SoonShiong, Founder
Paul Holt, CFO
Michael Sitrick, Independent Director

Stock Performance Indicators

Current Sentiment - NH

NantHealth Investor Sentiment
Macroaxis portfolio users are evenly split in their trading attitude regarding investing in NantHealth. What is your trading attitude regarding investing in NantHealth? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Build Optimal Portfolios

Align your risk with return expectations
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see also Stocks Correlation. Please also try Portfolio Quick Import module to import or update all your transactions via one easy-to-use interface.
vendors/bower_components/jquery.easy-pie-chart/dist/jquery.easypiechart.min.js">